Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis
It is postulated that lipoprotein (a) [Lp(a)] inhibits fibrinolysis, but this hypothesis has not been tested in humans due to the lack of specific Lp(a) lowering agents. Patients with elevated Lp(a) were randomized to antisense oligonucleotide [IONIS-APO(a)Rx] directed to apo(a) (n = 7) or placebo (...
Saved in:
| Published in | Journal of lipid research Vol. 60; no. 12; pp. 2082 - 2089 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.12.2019
The American Society for Biochemistry and Molecular Biology Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0022-2275 1539-7262 1539-7262 |
| DOI | 10.1194/jlr.P094763 |
Cover
Loading…
| Abstract | It is postulated that lipoprotein (a) [Lp(a)] inhibits fibrinolysis, but this hypothesis has not been tested in humans due to the lack of specific Lp(a) lowering agents. Patients with elevated Lp(a) were randomized to antisense oligonucleotide [IONIS-APO(a)Rx] directed to apo(a) (n = 7) or placebo (n = 10). Ex vivo plasma lysis times and antigen concentrations of plasminogen, factor XI, plasminogen activator inhibitor 1, thrombin activatable fibrinolysis inhibitor, and fibrinogen at baseline, day 85/92/99 (peak drug effect), and day 190 (3 months off drug) were measured. The mean ± SD baseline Lp(a) levels were 477.3 ± 55.9 nmol/l in IONIS-APO(a)Rx and 362.1 ± 89.9 nmol/l in placebo. The mean± SD percentage change in Lp(a) for IONIS-APO(a)Rx was −69.3 ± 12.2% versus −5.4 ± 6.9% placebo (P < 0.0010) at day 85/92/99 and −15.6 ± 8.9% versus 3.2 ± 12.2% (P = 0.003) at day 190. Clot lysis times and coagulation/fibrinolysis-related biomarkers showed no significant differences between IONIS-APO(a)Rx and placebo at all time points. Clot lysis times were not affected by exogenously added Lp(a) at concentrations up to 200 nmol/l to plasma with very low (12.5 nmol/l) Lp(a) levels, whereas recombinant apo(a) had a potent antifibrinolytic effect. In conclusion, potent reductions of Lp(a) in patients with highly elevated Lp(a) levels do not affect ex vivo measures of fibrinolysis; the relevance of any putative antifibrinolytic effects of Lp(a) in vivo needs further study. |
|---|---|
| AbstractList | It is postulated that lipoprotein (a) [Lp(a)] inhibits fibrinolysis, but this hypothesis has not been tested in humans due to the lack of specific Lp(a) lowering agents. Patients with elevated Lp(a) were randomized to antisense oligonucleotide [IONIS-APO(a)Rx] directed to apo(a) (n = 7) or placebo (n = 10). Ex vivo plasma lysis times and antigen concentrations of plasminogen, factor XI, plasminogen activator inhibitor 1, thrombin activatable fibrinolysis inhibitor, and fibrinogen at baseline, day 85/92/99 (peak drug effect), and day 190 (3 months off drug) were measured. The mean ± SD baseline Lp(a) levels were 477.3 ± 55.9 nmol/l in IONIS-APO(a)Rx and 362.1 ± 89.9 nmol/l in placebo. The mean± SD percentage change in Lp(a) for IONIS-APO(a)Rx was −69.3 ± 12.2% versus −5.4 ± 6.9% placebo (P < 0.0010) at day 85/92/99 and −15.6 ± 8.9% versus 3.2 ± 12.2% (P = 0.003) at day 190. Clot lysis times and coagulation/fibrinolysis-related biomarkers showed no significant differences between IONIS-APO(a)Rx and placebo at all time points. Clot lysis times were not affected by exogenously added Lp(a) at concentrations up to 200 nmol/l to plasma with very low (12.5 nmol/l) Lp(a) levels, whereas recombinant apo(a) had a potent antifibrinolytic effect. In conclusion, potent reductions of Lp(a) in patients with highly elevated Lp(a) levels do not affect ex vivo measures of fibrinolysis; the relevance of any putative antifibrinolytic effects of Lp(a) in vivo needs further study. It is postulated that lipoprotein (a) [Lp(a)] inhibits fibrinolysis, but this hypothesis has not been tested in humans due to the lack of specific Lp(a) lowering agents. Patients with elevated Lp(a) were randomized to antisense oligonucleotide [IONIS-APO(a) ] directed to apo(a) ( = 7) or placebo ( = 10). Ex vivo plasma lysis times and antigen concentrations of plasminogen, factor XI, plasminogen activator inhibitor 1, thrombin activatable fibrinolysis inhibitor, and fibrinogen at baseline, day 85/92/99 (peak drug effect), and day 190 (3 months off drug) were measured. The mean ± SD baseline Lp(a) levels were 477.3 ± 55.9 nmol/l in IONIS-APO(a) and 362.1 ± 89.9 nmol/l in placebo. The mean± SD percentage change in Lp(a) for IONIS-APO(a) was -69.3 ± 12.2% versus -5.4 ± 6.9% placebo ( < 0.0010) at day 85/92/99 and -15.6 ± 8.9% versus 3.2 ± 12.2% ( = 0.003) at day 190. Clot lysis times and coagulation/fibrinolysis-related biomarkers showed no significant differences between IONIS-APO(a) and placebo at all time points. Clot lysis times were not affected by exogenously added Lp(a) at concentrations up to 200 nmol/l to plasma with very low (12.5 nmol/l) Lp(a) levels, whereas recombinant apo(a) had a potent antifibrinolytic effect. In conclusion, potent reductions of Lp(a) in patients with highly elevated Lp(a) levels do not affect ex vivo measures of fibrinolysis; the relevance of any putative antifibrinolytic effects of Lp(a) in vivo needs further study. It is postulated that lipoprotein (a) [Lp(a)] inhibits fibrinolysis, but this hypothesis has not been tested in humans due to the lack of specific Lp(a) lowering agents. Patients with elevated Lp(a) were randomized to antisense oligonucleotide [IONIS-APO(a) Rx ] directed to apo(a) ( n = 7) or placebo ( n = 10). Ex vivo plasma lysis times and antigen concentrations of plasminogen, factor XI, plasminogen activator inhibitor 1, thrombin activatable fibrinolysis inhibitor, and fibrinogen at baseline, day 85/92/99 (peak drug effect), and day 190 (3 months off drug) were measured. The mean ± SD baseline Lp(a) levels were 477.3 ± 55.9 nmol/l in IONIS-APO(a) Rx and 362.1 ± 89.9 nmol/l in placebo. The mean± SD percentage change in Lp(a) for IONIS-APO(a) Rx was −69.3 ± 12.2% versus −5.4 ± 6.9% placebo ( P < 0.0010) at day 85/92/99 and −15.6 ± 8.9% versus 3.2 ± 12.2% ( P = 0.003) at day 190. Clot lysis times and coagulation/fibrinolysis-related biomarkers showed no significant differences between IONIS-APO(a) Rx and placebo at all time points. Clot lysis times were not affected by exogenously added Lp(a) at concentrations up to 200 nmol/l to plasma with very low (12.5 nmol/l) Lp(a) levels, whereas recombinant apo(a) had a potent antifibrinolytic effect. In conclusion, potent reductions of Lp(a) in patients with highly elevated Lp(a) levels do not affect ex vivo measures of fibrinolysis; the relevance of any putative antifibrinolytic effects of Lp(a) in vivo needs further study. It is postulated that lipoprotein (a) [Lp(a)] inhibits fibrinolysis, but this hypothesis has not been tested in humans due to the lack of specific Lp(a) lowering agents. Patients with elevated Lp(a) were randomized to antisense oligonucleotide [IONIS-APO(a)Rx] directed to apo(a) (n = 7) or placebo (n = 10). Ex vivo plasma lysis times and antigen concentrations of plasminogen, factor XI, plasminogen activator inhibitor 1, thrombin activatable fibrinolysis inhibitor, and fibrinogen at baseline, day 85/92/99 (peak drug effect), and day 190 (3 months off drug) were measured. The mean ± SD baseline Lp(a) levels were 477.3 ± 55.9 nmol/l in IONIS-APO(a)Rx and 362.1 ± 89.9 nmol/l in placebo. The mean± SD percentage change in Lp(a) for IONIS-APO(a)Rx was -69.3 ± 12.2% versus -5.4 ± 6.9% placebo (P < 0.0010) at day 85/92/99 and -15.6 ± 8.9% versus 3.2 ± 12.2% (P = 0.003) at day 190. Clot lysis times and coagulation/fibrinolysis-related biomarkers showed no significant differences between IONIS-APO(a)Rx and placebo at all time points. Clot lysis times were not affected by exogenously added Lp(a) at concentrations up to 200 nmol/l to plasma with very low (12.5 nmol/l) Lp(a) levels, whereas recombinant apo(a) had a potent antifibrinolytic effect. In conclusion, potent reductions of Lp(a) in patients with highly elevated Lp(a) levels do not affect ex vivo measures of fibrinolysis; the relevance of any putative antifibrinolytic effects of Lp(a) in vivo needs further study.It is postulated that lipoprotein (a) [Lp(a)] inhibits fibrinolysis, but this hypothesis has not been tested in humans due to the lack of specific Lp(a) lowering agents. Patients with elevated Lp(a) were randomized to antisense oligonucleotide [IONIS-APO(a)Rx] directed to apo(a) (n = 7) or placebo (n = 10). Ex vivo plasma lysis times and antigen concentrations of plasminogen, factor XI, plasminogen activator inhibitor 1, thrombin activatable fibrinolysis inhibitor, and fibrinogen at baseline, day 85/92/99 (peak drug effect), and day 190 (3 months off drug) were measured. The mean ± SD baseline Lp(a) levels were 477.3 ± 55.9 nmol/l in IONIS-APO(a)Rx and 362.1 ± 89.9 nmol/l in placebo. The mean± SD percentage change in Lp(a) for IONIS-APO(a)Rx was -69.3 ± 12.2% versus -5.4 ± 6.9% placebo (P < 0.0010) at day 85/92/99 and -15.6 ± 8.9% versus 3.2 ± 12.2% (P = 0.003) at day 190. Clot lysis times and coagulation/fibrinolysis-related biomarkers showed no significant differences between IONIS-APO(a)Rx and placebo at all time points. Clot lysis times were not affected by exogenously added Lp(a) at concentrations up to 200 nmol/l to plasma with very low (12.5 nmol/l) Lp(a) levels, whereas recombinant apo(a) had a potent antifibrinolytic effect. In conclusion, potent reductions of Lp(a) in patients with highly elevated Lp(a) levels do not affect ex vivo measures of fibrinolysis; the relevance of any putative antifibrinolytic effects of Lp(a) in vivo needs further study. |
| Author | Koschinsky, Marlys L. Tsimikas, Sotirios Yeang, Calvin Xia, Shuting Viney, Nicholas J. Boffa, Michael B. Marar, Tanya T. Witztum, Joseph L. |
| Author_xml | – sequence: 1 givenname: Michael B. surname: Boffa fullname: Boffa, Michael B. organization: Department of Biochemistry Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada – sequence: 2 givenname: Tanya T. surname: Marar fullname: Marar, Tanya T. organization: Department of Biochemistry Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada – sequence: 3 givenname: Calvin surname: Yeang fullname: Yeang, Calvin organization: Division of Endocrinology and Metabolism, University of California San Diego, La Jolla, CA – sequence: 4 givenname: Nicholas J. surname: Viney fullname: Viney, Nicholas J. organization: Ionis Pharmaceuticals, Carlsbad, CA – sequence: 5 givenname: Shuting surname: Xia fullname: Xia, Shuting organization: Ionis Pharmaceuticals, Carlsbad, CA – sequence: 6 givenname: Joseph L. surname: Witztum fullname: Witztum, Joseph L. organization: Division of Endocrinology and Metabolism, University of California San Diego, La Jolla, CA – sequence: 7 givenname: Marlys L. surname: Koschinsky fullname: Koschinsky, Marlys L. organization: Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada – sequence: 8 givenname: Sotirios surname: Tsimikas fullname: Tsimikas, Sotirios email: stsimikas@ucsd.edu organization: Division of Endocrinology and Metabolism, University of California San Diego, La Jolla, CA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31551368$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkt9rFDEQx4NU7LX65LvksSJbN8nuZvdFkOKPQsE-6HPIJpO7OfaSM8me9tl_3Jx3FSuFQCDzme9M5jtn5MQHD4S8ZPUlY0Pzdj3Fy9t6aGQnnpAFa8VQSd7xE7Koa84rzmV7Ss5SWtc1a5qOPSOngrUtE12_IL9uQwafaQQ7m4zB0-DodtJpo-mE27CNJY6eXujX9AfmFdW-nIwJfAIaJlwGP5sJQkYLtICreVOQNI9rMDlRGyBRHzLVzpUHCj_pDneBOhwj-jDdJUzPyVOnpwQvjvc5-fbxw9erz9XNl0_XV-9vKtMMIldG2FEM0nJjpdCSMek6oxvZN61rTN3yQXSjsdDxrh_ZoE099gzkWLuGDzAKcU6uD7o26LXaRtzoeKeCRvXnIcSl0jFj-Y3ivXWaAWeNFE0t29K9tmyQXDvJRWuK1ruD1nYeN2BNmWHU0wPRhxGPK7UMO9X1_SDZvpmLo0AM32dIWW0wGZgm7SHMSXFeMN6xri_oq39r_S1y72IB2AEwMaQUwSmDWe_dLKVxUqxW-01RZVPUcVNKzpv_cu5lH6fbAw3Fnx1CVMkgeAMWY7G1DBAfzfsNVzDVKg |
| CitedBy_id | crossref_primary_10_1016_j_artere_2024_04_001 crossref_primary_10_1055_s_0040_1718923 crossref_primary_10_1016_j_atherosclerosis_2023_04_012 crossref_primary_10_1007_s11239_021_02515_2 crossref_primary_10_1016_j_ejphar_2023_176232 crossref_primary_10_1016_j_arteri_2024_03_002 crossref_primary_10_1093_eurheartj_ehac361 crossref_primary_10_1016_j_ahjo_2021_100058 crossref_primary_10_1016_j_ejim_2020_04_036 crossref_primary_10_1007_s15027_023_3123_5 crossref_primary_10_1007_s11883_023_01102_5 crossref_primary_10_1016_j_cjco_2023_11_015 crossref_primary_10_1042_BCJ20240037 crossref_primary_10_1097_FJC_0000000000001429 crossref_primary_10_3389_fcvm_2022_808605 crossref_primary_10_1016_j_ecl_2024_05_009 crossref_primary_10_1038_s41569_023_00947_2 crossref_primary_10_3390_jcm11133625 crossref_primary_10_1007_s10557_021_07293_w crossref_primary_10_1016_j_cca_2024_119982 crossref_primary_10_1016_j_acvd_2021_10_009 crossref_primary_10_1007_s11883_021_00951_2 crossref_primary_10_1056_NEJMc2004861 crossref_primary_10_1016_j_phrs_2021_105689 crossref_primary_10_1055_s_0042_1757562 crossref_primary_10_3390_ijms25063537 crossref_primary_10_1016_j_artere_2024_07_008 crossref_primary_10_1038_s41569_024_01111_0 crossref_primary_10_3390_biomedicines11092353 crossref_primary_10_1016_j_thromres_2020_12_014 crossref_primary_10_1080_10408363_2023_2229915 crossref_primary_10_1161_JAHA_123_033654 crossref_primary_10_1016_j_atherosclerosis_2021_12_008 crossref_primary_10_1016_j_jacl_2024_08_004 crossref_primary_10_1016_j_metabol_2021_154706 crossref_primary_10_1161_ATV_0000000000000147 crossref_primary_10_12677_ACM_2023_131042 crossref_primary_10_1016_j_ijcha_2025_101599 crossref_primary_10_1097_HCO_0000000000001170 crossref_primary_10_1146_annurev_pharmtox_031023_100609 crossref_primary_10_1016_j_ajpc_2024_100651 crossref_primary_10_1016_j_atherosclerosis_2022_04_009 crossref_primary_10_1016_j_phrs_2023_106843 crossref_primary_10_1016_j_tcm_2023_01_003 |
| Cites_doi | 10.1016/S0140-6736(15)61252-1 10.1021/bi00015a028 10.1161/01.CIR.96.5.1612 10.1093/eurheartj/ehy862 10.1194/jlr.R060582 10.1016/j.jacl.2017.08.005 10.1194/jlr.P027235 10.1161/CIRCULATIONAHA.116.020838 10.1161/01.ATV.20.2.493 10.1016/j.jacc.2016.11.042 10.1038/s41569-018-0153-2 10.1182/blood.V98.10.2980 10.1111/j.1538-7836.2008.03183.x 10.1111/j.1399-0004.1997.tb04358.x 10.1161/CIRCULATIONAHA.115.016757 10.1038/srep05318 10.1161/01.ATV.10.2.240 10.1097/MOL.0000000000000171 10.1016/j.jacc.2017.11.014 10.1016/j.jacc.2012.01.078 10.1038/nm0395-256 10.1161/ATVBAHA.116.308011 10.1067/mva.2000.107757 10.3945/ajcn.115.124321 10.1016/j.jacc.2011.12.033 10.1016/S0140-6736(16)31009-1 10.1111/j.1538-7836.2007.02637.x 10.1074/jbc.M310425200 10.1182/blood.V82.2.392.392 10.1016/j.thromres.2014.01.024 10.1161/01.ATV.11.3.629 10.1161/CIRCRESAHA.118.313864 10.1194/jlr.M060210 10.1016/j.jacc.2010.10.052 10.1194/jlr.M040733 10.1161/ATVBAHA.112.248765 10.1074/jbc.M302780200 10.1016/j.thromres.2012.06.005 10.1161/01.ATV.18.9.1393 10.3324/haematol.2012.073833 10.1016/S0140-6736(17)32290-0 |
| ContentType | Journal Article |
| Copyright | 2019 Copyright © 2019 Boffa et al. Copyright © 2019 Boffa et al. Copyright © 2019 Boffa et al. 2019 Boffa et al. |
| Copyright_xml | – notice: 2019 Copyright © 2019 Boffa et al. – notice: Copyright © 2019 Boffa et al. – notice: Copyright © 2019 Boffa et al. 2019 Boffa et al. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1194/jlr.P094763 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: WRHA-DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry |
| EISSN | 1539-7262 |
| EndPage | 2089 |
| ExternalDocumentID | oai_doaj_org_article_28dfa1e214734075affad1972af7235c PMC6889713 31551368 10_1194_jlr_P094763 S0022227520310464 |
| Genre | Clinical Trial, Phase II Clinical Trial, Phase I Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -~X .55 .GJ 0SF 0VX 18M 29K 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. AAEDW AAFTH AAFWJ AAXUO AAYOK ABCQX ABOCM ACCCW ACGFO ACKIV ACNCT ACPRK ADBBV AENEX AEXQZ AFFNX AFOSN AFPKN AHPSJ AI. ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BAWUL BTFSW C1A CS3 D-I DIK DU5 E3Z EBS EJD F5P FDB FRP GROUPED_DOAJ GX1 H13 HH5 HYE H~9 J5H KQ8 L7B MVM OK1 P2P RHF RHI ROL RPM TBC TR2 TWZ VH1 W8F WH7 WOQ X7M XFK YHG YKV ZA5 ZGI ZXP ~KM 0R~ AALRI AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFPUW AIGII AITUG AKBMS AKRWK AKYEP CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c493t-c3db397d2cd73a7117f6ca47845f4c052936bcde6268b19ac0b81e7b0f429eb33 |
| IEDL.DBID | DOA |
| ISSN | 0022-2275 1539-7262 |
| IngestDate | Wed Aug 27 01:04:55 EDT 2025 Thu Aug 21 13:53:03 EDT 2025 Fri Jul 11 02:44:03 EDT 2025 Thu Jan 02 22:56:56 EST 2025 Tue Jul 01 01:14:38 EDT 2025 Thu Apr 24 23:09:27 EDT 2025 Fri Feb 23 02:44:59 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | apolipoprotein(a) thrombosis atherosclerotic cardiovascular disease |
| Language | English |
| License | This is an open access article under the CC BY license. http://creativecommons.org/licenses/by/4.0 https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2019 Boffa et al. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c493t-c3db397d2cd73a7117f6ca47845f4c052936bcde6268b19ac0b81e7b0f429eb33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This trial was registered at clinicaltrials.gov as NCT02160899 and NCT02414594. |
| OpenAccessLink | https://doaj.org/article/28dfa1e214734075affad1972af7235c |
| PMID | 31551368 |
| PQID | 2297126168 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_28dfa1e214734075affad1972af7235c pubmedcentral_primary_oai_pubmedcentral_nih_gov_6889713 proquest_miscellaneous_2297126168 pubmed_primary_31551368 crossref_citationtrail_10_1194_jlr_P094763 crossref_primary_10_1194_jlr_P094763 elsevier_sciencedirect_doi_10_1194_jlr_P094763 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-12-01 |
| PublicationDateYYYYMMDD | 2019-12-01 |
| PublicationDate_xml | – month: 12 year: 2019 text: 2019-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of lipid research |
| PublicationTitleAlternate | J Lipid Res |
| PublicationYear | 2019 |
| Publisher | Elsevier Inc The American Society for Biochemistry and Molecular Biology Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: The American Society for Biochemistry and Molecular Biology – name: Elsevier |
| References | Hervio, Chapman, Thillet, Loyau, Angles-Cano (bib9) 1993; 82 Rowland, Pullinger, Luke, Shiffman, Green, Movsesyan, Devlin, Malloy, Kane, Undas (bib28) 2014; 133 Caplice, Panetta, Peterson, Kleppe, Mueske, Kostner, Broze, Simari (bib27) 2001; 98 Helgadottir, Gretarsdottir, Thorleifsson, Holm, Patel, Gudnason, Jones, van Rij, Eapen, Baas (bib13) 2012; 60 Leibundgut, Arai, Orsoni, Yin, Scipione, Miller, Koschinsky, Chapman, Witztum, Tsimikas (bib22) 2012; 59 Scipione, Sayegh, Romagnuolo, Tsimikas, Marcovina, Boffa, Koschinsky (bib4) 2015; 56 Hancock, Boffa, Marcovina, Nesheim, Koschinsky (bib40) 2003; 278 Arai, Orsoni, Mallat, Tedgui, Witztum, Bruckert, Tselepis, Chapman, Tsimikas (bib35) 2012; 53 Giugliano, Pedersen, Park, De Ferrari, Gaciong, Ceska, Toth, Gouni-Berthold, Lopez-Miranda, Schiele (bib37) 2017; 390 Merki, Graham, Taleb, Leibundgut, Yang, Miller, Fu, Mullick, Lee, Willeit (bib38) 2011; 57 Loscalzo, Weinfeld, Fless, Scanu (bib7) 1990; 10 Feric, Boffa, Johnston, Koschinsky (bib24) 2008; 6 Palabrica, Liu, Aronovitz, Furie, Lawn, Furie (bib10) 1995; 1 Kamstrup, Tybjaerg-Hansen, Nordestgaard (bib14) 2012; 32 Falcó, Tormo, Estelles, Espana, Tormo, Gilabert, Velasco, Aznar (bib30) 2001; 86 Foody, Milberg, Robinson, Pearce, Jacobsen, Sprecher (bib16) 2000; 20 Rouy, Grailhe, Nigon, Chapman, Angles-Cano (bib8) 1991; 11 Leibundgut, Scipione, Yin, Schneider, Boffa, Green, Yang, Dennis, Witztum, Koschinsky (bib3) 2013; 54 Boffa, Koschinsky (bib42) 2019 van der Valk, Bekkering, Kroon, Yeang, Van den Bossche, van Buul, Ravandi, Nederveen, Verberne, Scipione (bib5) 2016; 134 Viney, van Capelleveen, Geary, Xia, Tami, Yu, Marcovina, Hughes, Graham, Crooke (bib19) 2016; 388 Yeang, Witztum, Tsimikas (bib39) 2015; 26 Fortunato, Bassiouny, Song, Kocharian, Glagov, Edelstein, Scanu (bib41) 2000; 32 Bouchareb, Mahmut, Nsaibia, Boulanger, Dahou, Lépine, Laflamme, Hadji, Couture, Trahan (bib23) 2015; 132 Tsimikas (bib1) 2017; 69 Tsimikas, Fazio, Ferdinand, Ginsberg, Koschinsky, Marcovina, Moriarty, Rader, Remaley, Reyes-Soffer (bib2) 2018; 71 Varvel, McConnell, Tsimikas (bib25) 2016; 36 Undas, Plicner, Stepien, Drwila, Sadowski (bib32) 2007; 5 Månsson, Kalies, Bergstrom, Schmidt, Legnehed, Hulten, Amrot-Fors, Gustafsson, Knecht (bib33) 2014; 4 Edelstein, Pfaffinger, Hinman, Miller, Lipkind, Tsimikas, Bergmark, Getz, Witztum, Scanu (bib34) 2003; 278 Goldenberg, Bernard, Hillhouse, Armstrong-Wells, Galinkin, Knapp-Clevenger, Jacobson, Marcovina, Manco-Johnson (bib15) 2013; 98 Superko, Zhao, Hodis, Guyton (bib20) 2017; 11 Chandler, Song, Lin, Zhang, Sesso, Mora, Giovannucci, Rexrode, Moorthy, Li (bib29) 2016; 103 Tsimikas, Viney, Hughes, Singleton, Graham, Baker, Burkey, Yang, Marcovina, Geary (bib18) 2015; 386 Rand, Sangrar, Hancock, Taylor, Marcovina, Packham, Koschinsky (bib26) 1998; 18 Undas, Ciesla-Dul, Drazkiewicz, Sadowski (bib31) 2012; 130 Mooser, Marcovina, Wang, Hobbs (bib36) 1997; 52 Boffa, Koschinsky (bib6) 2016; 57 Stiekema, Stroes, Verweij, Kassahun, Chen, Wasserman, Sabatine, Mani, Fayad (bib21) 2018; 40 Biemond, Friederich, Koschinsky, Levi, Sangrar, Xia, Buller, ten Cate (bib12) 1997; 96 Tsimikas (bib17) 2019; 124 Sangrar, Bajzar, Nesheim, Koschinsky (bib11) 1995; 34 Tsimikas (10.1194/jlr.P094763_bib1) 2017; 69 Rand (10.1194/jlr.P094763_bib26) 1998; 18 van der Valk (10.1194/jlr.P094763_bib5) 2016; 134 Scipione (10.1194/jlr.P094763_bib4) 2015; 56 Leibundgut (10.1194/jlr.P094763_bib22) 2012; 59 Chandler (10.1194/jlr.P094763_bib29) 2016; 103 Caplice (10.1194/jlr.P094763_bib27) 2001; 98 Feric (10.1194/jlr.P094763_bib24) 2008; 6 Yeang (10.1194/jlr.P094763_bib39) 2015; 26 Rowland (10.1194/jlr.P094763_bib28) 2014; 133 Undas (10.1194/jlr.P094763_bib31) 2012; 130 Arai (10.1194/jlr.P094763_bib35) 2012; 53 Goldenberg (10.1194/jlr.P094763_bib15) 2013; 98 Varvel (10.1194/jlr.P094763_bib25) 2016; 36 Leibundgut (10.1194/jlr.P094763_bib3) 2013; 54 Giugliano (10.1194/jlr.P094763_bib37) 2017; 390 Hervio (10.1194/jlr.P094763_bib9) 1993; 82 Mooser (10.1194/jlr.P094763_bib36) 1997; 52 Kamstrup (10.1194/jlr.P094763_bib14) 2012; 32 Foody (10.1194/jlr.P094763_bib16) 2000; 20 Loscalzo (10.1194/jlr.P094763_bib7) 1990; 10 Stiekema (10.1194/jlr.P094763_bib21) 2018; 40 Undas (10.1194/jlr.P094763_bib32) 2007; 5 Superko (10.1194/jlr.P094763_bib20) 2017; 11 Månsson (10.1194/jlr.P094763_bib33) 2014; 4 Boffa (10.1194/jlr.P094763_bib6) 2016; 57 Sangrar (10.1194/jlr.P094763_bib11) 1995; 34 Merki (10.1194/jlr.P094763_bib38) 2011; 57 Biemond (10.1194/jlr.P094763_bib12) 1997; 96 Viney (10.1194/jlr.P094763_bib19) 2016; 388 Tsimikas (10.1194/jlr.P094763_bib2) 2018; 71 Fortunato (10.1194/jlr.P094763_bib41) 2000; 32 Boffa (10.1194/jlr.P094763_bib42) 2019 Edelstein (10.1194/jlr.P094763_bib34) 2003; 278 Palabrica (10.1194/jlr.P094763_bib10) 1995; 1 Bouchareb (10.1194/jlr.P094763_bib23) 2015; 132 Helgadottir (10.1194/jlr.P094763_bib13) 2012; 60 Falcó (10.1194/jlr.P094763_bib30) 2001; 86 Tsimikas (10.1194/jlr.P094763_bib18) 2015; 386 Tsimikas (10.1194/jlr.P094763_bib17) 2019; 124 Rouy (10.1194/jlr.P094763_bib8) 1991; 11 Hancock (10.1194/jlr.P094763_bib40) 2003; 278 |
| References_xml | – volume: 57 start-page: 1611 year: 2011 end-page: 1621 ident: bib38 article-title: Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice publication-title: J. Am. Coll. Cardiol. – volume: 59 start-page: 1426 year: 2012 end-page: 1437 ident: bib22 article-title: Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction publication-title: J. Am. Coll. Cardiol. – volume: 130 start-page: e184 year: 2012 end-page: e187 ident: bib31 article-title: Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform publication-title: Thromb. Res. – volume: 96 start-page: 1612 year: 1997 end-page: 1615 ident: bib12 article-title: Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo publication-title: Circulation. – volume: 26 start-page: 169 year: 2015 end-page: 178 ident: bib39 article-title: ‘LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering publication-title: Curr. Opin. Lipidol. – volume: 82 start-page: 392 year: 1993 end-page: 397 ident: bib9 article-title: Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? publication-title: Blood. – volume: 36 start-page: 2239 year: 2016 end-page: 2245 ident: bib25 article-title: Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 18 start-page: 1393 year: 1998 end-page: 1399 ident: bib26 article-title: Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 69 start-page: 692 year: 2017 end-page: 711 ident: bib1 article-title: A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies publication-title: J. Am. Coll. Cardiol. – volume: 57 start-page: 745 year: 2016 end-page: 757 ident: bib6 article-title: Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? publication-title: J. Lipid Res. – volume: 86 start-page: 92 year: 2001 end-page: 98 ident: bib30 article-title: Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy publication-title: Haematologica. – volume: 388 start-page: 2239 year: 2016 end-page: 2253 ident: bib19 article-title: Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials publication-title: Lancet. – volume: 71 start-page: 177 year: 2018 end-page: 192 ident: bib2 article-title: NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis publication-title: J. Am. Coll. Cardiol. – volume: 11 start-page: 1309 year: 2017 end-page: 1317 ident: bib20 article-title: Niacin and heart disease prevention: engraving its tombstone is a mistake publication-title: J. Clin. Lipidol. – volume: 56 start-page: 2273 year: 2015 end-page: 2285 ident: bib4 article-title: Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a) publication-title: J. Lipid Res. – volume: 32 start-page: 555 year: 2000 end-page: 563 ident: bib41 article-title: Apolipoprotein (a) fragments in relation to human carotid plaque instability publication-title: J. Vasc. Surg. – volume: 134 start-page: 611 year: 2016 end-page: 624 ident: bib5 article-title: Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans publication-title: Circulation. – volume: 1 start-page: 256 year: 1995 end-page: 259 ident: bib10 article-title: Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis publication-title: Nat. Med. – volume: 98 start-page: 2980 year: 2001 end-page: 2987 ident: bib27 article-title: Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis publication-title: Blood. – volume: 278 start-page: 23260 year: 2003 end-page: 23269 ident: bib40 article-title: Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces publication-title: J. Biol. Chem. – volume: 5 start-page: 1988 year: 2007 end-page: 1990 ident: bib32 article-title: Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine publication-title: J. Thromb. Haemost. – volume: 34 start-page: 5151 year: 1995 end-page: 5157 ident: bib11 article-title: Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation publication-title: Biochemistry. – volume: 132 start-page: 677 year: 2015 end-page: 690 ident: bib23 article-title: Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve publication-title: Circulation. – volume: 6 start-page: 2113 year: 2008 end-page: 2120 ident: bib24 article-title: Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation publication-title: J. Thromb. Haemost. – volume: 53 start-page: 1670 year: 2012 end-page: 1678 ident: bib35 article-title: Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia publication-title: J. Lipid Res. – volume: 4 start-page: 5318 year: 2014 ident: bib33 article-title: Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo publication-title: Sci. Rep. – volume: 20 start-page: 493 year: 2000 end-page: 499 ident: bib16 article-title: Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 278 start-page: 52841 year: 2003 end-page: 52847 ident: bib34 article-title: Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a) publication-title: J. Biol. Chem. – volume: 390 start-page: 1962 year: 2017 end-page: 1971 ident: bib37 article-title: Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial publication-title: Lancet. – volume: 60 start-page: 722 year: 2012 end-page: 729 ident: bib13 article-title: Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism publication-title: J. Am. Coll. Cardiol. – volume: 103 start-page: 1397 year: 2016 end-page: 1407 ident: bib29 article-title: Lipid biomarkers and long-term risk of cancer in the Women's Health Study publication-title: Am. J. Clin. Nutr. – volume: 133 start-page: 863 year: 2014 end-page: 867 ident: bib28 article-title: Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties publication-title: Thromb. Res. – volume: 52 start-page: 387 year: 1997 end-page: 392 ident: bib36 article-title: High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay publication-title: Clin. Genet. – volume: 386 start-page: 1472 year: 2015 end-page: 1483 ident: bib18 article-title: Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study publication-title: Lancet. – volume: 98 start-page: 802 year: 2013 end-page: 807 ident: bib15 article-title: Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children publication-title: Haematologica. – volume: 54 start-page: 2815 year: 2013 end-page: 2830 ident: bib3 article-title: Determinants of binding of oxidized phospholipids on apolipoprotein(a) and lipoprotein(a) publication-title: J. Lipid Res. – volume: 32 start-page: 1732 year: 2012 end-page: 1741 ident: bib14 article-title: Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 124 start-page: 405 year: 2019 end-page: 415 ident: bib17 article-title: Potential causality and emerging medical therapies for lipoprotein(a) and its associated oxidized phospholipids in calcific aortic valve stenosis publication-title: Circ. Res. – volume: 11 start-page: 629 year: 1991 end-page: 638 ident: bib8 article-title: Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu publication-title: Arterioscler. Thromb. – volume: 10 start-page: 240 year: 1990 end-page: 245 ident: bib7 article-title: Lipoprotein(a), fibrin binding, and plasminogen activation publication-title: Arteriosclerosis. – volume: 40 start-page: 2775 year: 2018 end-page: 2781 ident: bib21 article-title: Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment publication-title: Eur. Heart J. – year: 2019 ident: bib42 article-title: Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease publication-title: Nat. Rev. Cardiol. – volume: 386 start-page: 1472 year: 2015 ident: 10.1194/jlr.P094763_bib18 article-title: Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study publication-title: Lancet. doi: 10.1016/S0140-6736(15)61252-1 – volume: 34 start-page: 5151 year: 1995 ident: 10.1194/jlr.P094763_bib11 article-title: Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation publication-title: Biochemistry. doi: 10.1021/bi00015a028 – volume: 96 start-page: 1612 year: 1997 ident: 10.1194/jlr.P094763_bib12 article-title: Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo publication-title: Circulation. doi: 10.1161/01.CIR.96.5.1612 – volume: 40 start-page: 2775 year: 2018 ident: 10.1194/jlr.P094763_bib21 article-title: Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehy862 – volume: 57 start-page: 745 year: 2016 ident: 10.1194/jlr.P094763_bib6 article-title: Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? publication-title: J. Lipid Res. doi: 10.1194/jlr.R060582 – volume: 11 start-page: 1309 year: 2017 ident: 10.1194/jlr.P094763_bib20 article-title: Niacin and heart disease prevention: engraving its tombstone is a mistake publication-title: J. Clin. Lipidol. doi: 10.1016/j.jacl.2017.08.005 – volume: 53 start-page: 1670 year: 2012 ident: 10.1194/jlr.P094763_bib35 article-title: Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia publication-title: J. Lipid Res. doi: 10.1194/jlr.P027235 – volume: 134 start-page: 611 year: 2016 ident: 10.1194/jlr.P094763_bib5 article-title: Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans publication-title: Circulation. doi: 10.1161/CIRCULATIONAHA.116.020838 – volume: 20 start-page: 493 year: 2000 ident: 10.1194/jlr.P094763_bib16 article-title: Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/01.ATV.20.2.493 – volume: 69 start-page: 692 year: 2017 ident: 10.1194/jlr.P094763_bib1 article-title: A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2016.11.042 – year: 2019 ident: 10.1194/jlr.P094763_bib42 article-title: Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease publication-title: Nat. Rev. Cardiol. doi: 10.1038/s41569-018-0153-2 – volume: 98 start-page: 2980 year: 2001 ident: 10.1194/jlr.P094763_bib27 article-title: Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis publication-title: Blood. doi: 10.1182/blood.V98.10.2980 – volume: 6 start-page: 2113 year: 2008 ident: 10.1194/jlr.P094763_bib24 article-title: Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation publication-title: J. Thromb. Haemost. doi: 10.1111/j.1538-7836.2008.03183.x – volume: 52 start-page: 387 year: 1997 ident: 10.1194/jlr.P094763_bib36 article-title: High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay publication-title: Clin. Genet. doi: 10.1111/j.1399-0004.1997.tb04358.x – volume: 132 start-page: 677 year: 2015 ident: 10.1194/jlr.P094763_bib23 article-title: Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve publication-title: Circulation. doi: 10.1161/CIRCULATIONAHA.115.016757 – volume: 4 start-page: 5318 year: 2014 ident: 10.1194/jlr.P094763_bib33 article-title: Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo publication-title: Sci. Rep. doi: 10.1038/srep05318 – volume: 10 start-page: 240 year: 1990 ident: 10.1194/jlr.P094763_bib7 article-title: Lipoprotein(a), fibrin binding, and plasminogen activation publication-title: Arteriosclerosis. doi: 10.1161/01.ATV.10.2.240 – volume: 26 start-page: 169 year: 2015 ident: 10.1194/jlr.P094763_bib39 article-title: ‘LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering publication-title: Curr. Opin. Lipidol. doi: 10.1097/MOL.0000000000000171 – volume: 71 start-page: 177 year: 2018 ident: 10.1194/jlr.P094763_bib2 article-title: NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2017.11.014 – volume: 60 start-page: 722 year: 2012 ident: 10.1194/jlr.P094763_bib13 article-title: Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2012.01.078 – volume: 1 start-page: 256 year: 1995 ident: 10.1194/jlr.P094763_bib10 article-title: Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis publication-title: Nat. Med. doi: 10.1038/nm0395-256 – volume: 36 start-page: 2239 year: 2016 ident: 10.1194/jlr.P094763_bib25 article-title: Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/ATVBAHA.116.308011 – volume: 32 start-page: 555 year: 2000 ident: 10.1194/jlr.P094763_bib41 article-title: Apolipoprotein (a) fragments in relation to human carotid plaque instability publication-title: J. Vasc. Surg. doi: 10.1067/mva.2000.107757 – volume: 103 start-page: 1397 year: 2016 ident: 10.1194/jlr.P094763_bib29 article-title: Lipid biomarkers and long-term risk of cancer in the Women's Health Study publication-title: Am. J. Clin. Nutr. doi: 10.3945/ajcn.115.124321 – volume: 59 start-page: 1426 year: 2012 ident: 10.1194/jlr.P094763_bib22 article-title: Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2011.12.033 – volume: 388 start-page: 2239 year: 2016 ident: 10.1194/jlr.P094763_bib19 article-title: Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials publication-title: Lancet. doi: 10.1016/S0140-6736(16)31009-1 – volume: 5 start-page: 1988 year: 2007 ident: 10.1194/jlr.P094763_bib32 article-title: Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine publication-title: J. Thromb. Haemost. doi: 10.1111/j.1538-7836.2007.02637.x – volume: 278 start-page: 52841 year: 2003 ident: 10.1194/jlr.P094763_bib34 article-title: Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a) publication-title: J. Biol. Chem. doi: 10.1074/jbc.M310425200 – volume: 82 start-page: 392 year: 1993 ident: 10.1194/jlr.P094763_bib9 article-title: Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? publication-title: Blood. doi: 10.1182/blood.V82.2.392.392 – volume: 133 start-page: 863 year: 2014 ident: 10.1194/jlr.P094763_bib28 article-title: Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties publication-title: Thromb. Res. doi: 10.1016/j.thromres.2014.01.024 – volume: 11 start-page: 629 year: 1991 ident: 10.1194/jlr.P094763_bib8 article-title: Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu publication-title: Arterioscler. Thromb. doi: 10.1161/01.ATV.11.3.629 – volume: 124 start-page: 405 year: 2019 ident: 10.1194/jlr.P094763_bib17 article-title: Potential causality and emerging medical therapies for lipoprotein(a) and its associated oxidized phospholipids in calcific aortic valve stenosis publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.118.313864 – volume: 56 start-page: 2273 year: 2015 ident: 10.1194/jlr.P094763_bib4 article-title: Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a) publication-title: J. Lipid Res. doi: 10.1194/jlr.M060210 – volume: 57 start-page: 1611 year: 2011 ident: 10.1194/jlr.P094763_bib38 article-title: Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2010.10.052 – volume: 54 start-page: 2815 year: 2013 ident: 10.1194/jlr.P094763_bib3 article-title: Determinants of binding of oxidized phospholipids on apolipoprotein(a) and lipoprotein(a) publication-title: J. Lipid Res. doi: 10.1194/jlr.M040733 – volume: 32 start-page: 1732 year: 2012 ident: 10.1194/jlr.P094763_bib14 article-title: Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/ATVBAHA.112.248765 – volume: 278 start-page: 23260 year: 2003 ident: 10.1194/jlr.P094763_bib40 article-title: Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces publication-title: J. Biol. Chem. doi: 10.1074/jbc.M302780200 – volume: 130 start-page: e184 year: 2012 ident: 10.1194/jlr.P094763_bib31 article-title: Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform publication-title: Thromb. Res. doi: 10.1016/j.thromres.2012.06.005 – volume: 18 start-page: 1393 year: 1998 ident: 10.1194/jlr.P094763_bib26 article-title: Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/01.ATV.18.9.1393 – volume: 98 start-page: 802 year: 2013 ident: 10.1194/jlr.P094763_bib15 article-title: Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children publication-title: Haematologica. doi: 10.3324/haematol.2012.073833 – volume: 86 start-page: 92 year: 2001 ident: 10.1194/jlr.P094763_bib30 article-title: Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy publication-title: Haematologica. – volume: 390 start-page: 1962 year: 2017 ident: 10.1194/jlr.P094763_bib37 article-title: Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial publication-title: Lancet. doi: 10.1016/S0140-6736(17)32290-0 |
| SSID | ssj0014461 |
| Score | 2.492198 |
| Snippet | It is postulated that lipoprotein (a) [Lp(a)] inhibits fibrinolysis, but this hypothesis has not been tested in humans due to the lack of specific Lp(a)... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2082 |
| SubjectTerms | Adolescent Adult Aged apolipoprotein(a) atherosclerotic cardiovascular disease Female Fibrinolysis - genetics Humans Lipoprotein(a) - blood Lipoprotein(a) - genetics Male Middle Aged Oligonucleotides, Antisense - genetics Patient-Oriented and Epidemiological Research thrombosis Young Adult |
| Title | Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis |
| URI | https://dx.doi.org/10.1194/jlr.P094763 https://www.ncbi.nlm.nih.gov/pubmed/31551368 https://www.proquest.com/docview/2297126168 https://pubmed.ncbi.nlm.nih.gov/PMC6889713 https://doaj.org/article/28dfa1e214734075affad1972af7235c |
| Volume | 60 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1db9MwFLXQeIAXBBsf5WO6SBMCpGyN7cTOY5mYJiahCTGxt8hxbAjq7KpJJ3jmj3PtJFULk3hB6lNjpU7vTe459s05hBxIK6fWZCEClUh4kdoEwVGW5DkWDMVD32vstviYn17wD5fZ5YbVV-gJ6-WB-z_uiMraqtQEOx2G5CNT1qo6eGUpKyjLdHj6Ys0bydSwf4AkJx11wikV2fBmHjL2o-_z5eE5kpqo_LlRi6Jk_1ZJ-hty_tk5uVGKTu6TewOGhFk_9wfklnG7ZG_mkD9f_YRXELs643L5LrlzPDq67ZFf5x4RcgfLINcaAgLewgLh85WCebPwUbOhcfBavYGwPgvK4Se4NbvWgJ83X70L8se-a2oDODAa_EG7qsJiTgu1Ny0434GKTSJgfsB1c-3BhtcKnI_iJw_Jxcn7z8enyWDCkGhesC7RrK4Qs9RU14IpkabC5lpxIXlmuQ77hCyvdG2QGMkqLZSeVjI1opparHTI1NkjsuO8M08IcF4XqqBGI2jimlOVS50ro5ktWEW1nZC3YzhKPSiUB6OMeRmZSsFLjF05xG5CDtaDF70wx83D3oW4rocENe34BeZYOeRY-a8cm5DDMSvKAZj0gANP1dz8qy_H3CkxxmEPRjnjV21JaSFSZK25nJDHfS6t58ai2044IraybGvy20dc8y1KgudS4nnZ0_9xtc_IXUSFRd-z85zsdMuVeYHIq6v2ye3Z2acvZ_vxZvsNAz0wJw |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Potent+reduction+of+plasma+lipoprotein+%28a%29+with+an+antisense+oligonucleotide+in+human+subjects+does+not+affect+ex+vivo+fibrinolysis&rft.jtitle=Journal+of+lipid+research&rft.au=Boffa%2C+Michael+B.&rft.au=Marar%2C+Tanya+T.&rft.au=Yeang%2C+Calvin&rft.au=Viney%2C+Nicholas+J.&rft.date=2019-12-01&rft.pub=The+American+Society+for+Biochemistry+and+Molecular+Biology&rft.issn=0022-2275&rft.eissn=1539-7262&rft.volume=60&rft.issue=12&rft.spage=2082&rft.epage=2089&rft_id=info:doi/10.1194%2Fjlr.P094763&rft_id=info%3Apmid%2F31551368&rft.externalDocID=PMC6889713 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2275&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2275&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2275&client=summon |